Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs

Blood Cells, Molecules & Diseases
Tereza LopotováJana Moravcová

Abstract

Although the mechanism of action of leukemic oncogene Wilms' tumor gene 1 (WT1) remains unclear, WT1 has already been used in monitoring of patients with acute myeloid leukemia (AML) and it is being tested for immunotherapy. More detailed understanding of the role of WT1 in leukemia may improve its utilization. At least 36 isoforms may be produced. Four major variants denoted as -5/-KTS, -5/+KTS, +5/-KTS and +5/+KTS are produced by combining splicing of exon 5 and KTS sequence. In this study, we report applicability of newly developed real-time RT PCRs enabling for the first time full quantification of the four major WT1 splicing variants. Following careful optimization and testing of quantification reliability of four assays, we analyzed 34 samples of patients with AML and 12 samples of patients with chronic myeloid leukemia (CML) at the time of diagnosis. Analyses of five more CML patients provided insight into WT1 variants expression kinetics. We found predominance of +5/+KTS in both diagnoses. Comparison of WT1 variant expression in AML and CML patients' groups differing in response to therapy suggested possible importance of particular WT1 variant levels as markers of further disease course.

References

Mar 15, 1994·Genes & Development·P M SharmaS Sukumar
Apr 12, 1996·The Journal of Biological Chemistry·W Bruening, J Pelletier
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·A CaricasoleA Ward
Aug 7, 1999·The Journal of Biological Chemistry·V ScharnhorstA G Jochemsen
May 16, 2006·The Journal of Biological Chemistry·Anwar HossainGrady F Saunders
Aug 11, 2007·Leukemia·W GlienkeL Bergmann
Nov 1, 2008·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Yoshihiro Oka, Ichiro Kawase
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele BaccaraniUNKNOWN European LeukemiaNet

❮ Previous
Next ❯

Citations

Nov 12, 2013·Leukemia Research·Irene LunaMiguel A Sanz
May 20, 2014·Translational Oncology·Shuang ZhaoGary D Luker
Nov 17, 2020·Frontiers in Genetics·Ying QuHong Zhou
Jan 7, 2019·Blood Cells, Molecules & Diseases·Laurane CottinDamien Luque Paz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.